DUBLIN--(BUSINESS WIRE)--The "Metabolomics Market by Product (GC, UPLC, CE, Surface based Mass Analysis), Application (Biomarker Discovery, Drug Discovery, Functional Genomics), Indication (Cardiology, Oncology, Inborn Errors), End User (Academic Institute, CROs) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The global metabolomics market size is projected to reach USD 4.1 billion by 2025 from USD 1.9 billion in 2020, at a CAGR of 13.4% during the forecast period.
The major factors driving the growth of this market are the growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, growing demand for personalized medicine, and increasing use of metabolomics in toxicology testing are driving the growth of the global metabolomics industry. However, issues related to data examination & data processing in metabolomics and the high cost of tools and instruments are likely to restrain the market growth to a certain extent.
By Product & Service, the metabolomics instrument accounted for the largest share of the metabolomics market.
The metabolomics instrument segment is expected to account for the largest market share in 2020. Factors such as the technological advancements in analytical instruments in terms of miniaturization, automation, and computerization; increase in the number of research-related activities worldwide in the field of medicine, nutraceuticals, and metabolomics; and strengthening healthcare infrastructure in developing nations for efficient disease diagnosis and treatment are expected to propel the growth of this segment during the forecast period
By application, the biomarker discovery segment accounted for the largest share of the metabolomics market.
The biomarker discovery segment is expected to account for the largest market share in 2020. The use of metabolic biomarkers to assess the pathophysiological health status of patients is increasing. In recent years, as a result of significant technological advancements, metabolomics has become a vital tool in discovering biomarkers.
By Indication, the Cancer segment expected to grow at the fastest growth rate during the forecast period.
Based on indication, the metabolomics market has been segmented into cancer, cardiovascular disorders, neurological disorders, metabolic disorders, inborn errors of metabolism, and other indications (respiratory and infectious diseases. The cancer segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the increasing number of patients who have cancer and the subsequent
increase in the demand for cancer therapies.
By End-user, Academic and Research Institutes accounted for the largest share of the metabolomics market.
The academic and research institutes segment accounted for the largest share of the metabolomics market in 2020. The increasing number of research activities in the field of metabolomics and funding to the academic and research institutes to conduct metabolomics research are the factors responsible for the largest share of the segment.
Asia Pacific: The fastest-growing region in the metabolomics market.
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period. Several global pharmaceutical firms have entered the APAC market to tap the significant growth opportunities in emerging Asian countries and lower their production costs by shifting their drug discovery R&D operations and manufacturing to the region. A large number of qualified researchers and low-cost operations in APAC countries, such as India and China, are some of the major factors supporting this trend.
North America: The largest share of the metabolomics market.
North America, which includes the US and Canada, accounted for the largest share of the metabolomics market. The large share of the North America region can be attributed to the presence of major players operating in the metabolomics market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.
Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs.
- Availability of Government and Private Funding for Metabolomics Research
- Increasing Pharmaceutical and Biotech R&D Expenditure
- Growing Demand for Personalized Medicine
- Issues Related to Data Examination and Processing
- High Cost of Tools and Instruments
- Biomarker Development
- Lucrative Opportunities in Emerging Markets
- Complexity and Diversity of Biological Samples
- Dearth of Skilled Researchers
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Bruker Corporation
- Danaher Corporation
- Dani Instruments
- GE Healthcare
- Gl Sciences
- Hitachi High-Technologies Corporation
- Human Metabolome Technologies, Inc.
- Jasco, Inc.
- Kore Technology
- Leco Corporation
- Merck KGaA
- Metabolon, Inc.
- Perkinelmer, Inc.
- Scion Instruments
- Shimadzu Corporation
- Sri Instruments
- Thermo Fisher Scientific Inc.
- Waters Corporation
For more information about this report visit https://www.researchandmarkets.com/r/veeimj.
Laura Wood, Senior Press Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900